Rethink Head Lice Treatment.

The latest evidence-based clinical data provides appropriate criteria for therapy.

Explore the Latest Guidance

Leading head lice experts discuss why conventional approaches to determining the best course of treatment are no longer viable.

Head lice resistance is rendering OTCs ineffective

Clinical criteria for determining optimal treatment

The negative impact of social stigma on mental health

Resolve The Lice Cycle With Spinosad Topical Suspension 0.9%

The only FDA-approved prescription head lice treatment with proven safety and efficacy in head-to-head clinical trials.

Take Decisive Action

Put an end to the lice cycle with Spinosad Topical Suspension 0.9%—the only prescription head lice treatment that has demonstrated superior efficacy to Nix^® (permethrin 1%) in head-to-head clinical trials.¹

Among the least toxic of
pediculicides

Administration for active
households

Education that breaks the
stigma

No known resistance to spinosad (the molecule) in head lice²

Find Spinosad Topical Suspension 0.9% Near You

Formulary & Pharmacy Lookup tools for immediate access to insurance and product availability information.

Connect with a Rep

Request a visit and a Spinosad Topical Suspension 0.9% rep will share the evidence-based product information in person with you and your staff.

Nix^® is a registered trademark of Prestige Brands, Inc.

References

Stough D, Shellabarger S, Quiring J, Gabrielsen A. Efficacy and safety of spinosad and permethrin crème rinses for pediculosis capitis (head lice). Pediatrics. 2009;124(3): e389-395.
DOW AgroSciences 2001.
Spinosad Topical Suspension 0.9% Prescribing Information
Data on file.

SPN-RRW1-000

Important Safety Information

Indication
Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:

Important Safety Information

Indication
Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.